Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC-T vs ET Regimen in Adjuvant Treatment of Breast Cancer
NCT01134523Phase 3Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- May 2010
- Primary completion
- May 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of epirubicin, paclitaxel in breast cancer, sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
epirubicinpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01134523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01134523.